MRK - Urovant IPO: Phase 3 Clinical Data To Be Released In 2019
Conducting biopharmaceutical research initiated by Merck (MRK) and with a massive market opportunity, Urovant (UROV) seems an interesting name to be followed once the IPO goes live. With that, the facts that the company was incorporated in Cayman and Roivant Sciences Ltd. controls the company are not ideal. Finally, lack of institutional investors is another relevant worrying feature.
Source: Prospectus
Investment bankers leading the IPO are well-known financial institutions. It is a beneficial fact that will retain the attention of many investors:
Source: Prospectus